Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured

Thrombosis Research

Volumn 118, Issue 2, 2006, Pages 281-287

  Dahm, Anders E A ^a   Iversen, Per Ole ^a,b   Hjeltnes, Nils ^c   Sandset, Per Morten ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c SUNNAAS REHABILITATION HOSPITAL   (Norway)

Author keywords

Circadian variation; Tetraplegia; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

ANTIGEN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; ASSAY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMPARATIVE STUDY; HUMAN; INDIVIDUALIZATION; MALE; MEASUREMENT; PRIORITY JOURNAL; QUADRIPLEGIA; SPINAL CORD INJURY;

ADULT; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; QUADRIPLEGIA; SPINAL CORD INJURIES;

EID: 33744520027     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.07.021     Document Type: Article

References (35)

1. Bajaj M.S., Kuppuswamy M.N., Saito H., Spitzer S.G., and Bajaj S.P. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A 87 (1990) 8869-8873
2. Warn-Cramer B.J., Rao L.V., Maki S.L., and Rapaport S.I. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 60 (1988) 453-456
3. Wesselschmidt R., Likert K., Girard T., Wun T.C., and Broze Jr. G.J. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 79 (1992) 2004-2010
4. Sanders N.L., Bajaj S.P., Zivelin A., and Rapaport S.I. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 66 (1985) 204-212
5. Sandset P.M., Warn-Cramer B.J., Maki S.L., and Rapaport S.I. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 78 (1991) 1496-1502
6. Sandset P.M., Warn-Cramer B.J., Rao L.V., Maki S.L., and Rapaport S.I. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A 88 (1991) 708-712
7. Holst J., Lindblad B., Bergqvist D., Nordfang O., Ostergaard P.B., Petersen J.L., et al. Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model. Haemostasis 23 Suppl 1 (1993) 112-117
8. Huang Z.F., Higuchi D., Lasky N., and Broze Jr. G.J. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90 (1997) 944-951
9. Hansen J.B., Huseby N.E., Sandset P.M., Svensson B., Lyngmo V., and Nordoy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 14 (1994) 223-229
10. Hubbard A.R., and Jennings C.A. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb Res 46 (1987) 527-537
11. Sandset P.M., Abildgaard U., and Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50 (1988) 803-813
12. Novotny W.F., Girard T.J., Miletich J.P., and Broze Jr. G.J. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72 (1988) 2020-2025
13. Dahm A., van Hylckama Vlieg A., Bendz B., Rosendaal F., Bertina R.M., and Sandset P.M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101 (2003) 4387-4392
14. Hoibraaten E., Qvigstad E., Andersen T.O., Mowinckel M.C., and Sandset P.M. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial. Thromb Haemost 85 (2001) 775-781
15. Bladbjerg E.M., Skouby S.O., Andersen L.F., and Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 17 (2002) 3235-3241
16. Bladbjerg E.M., Madsen J.S., Kristensen S.R., Abrahamsen B., Brixen K., Mosekilde L., et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 1 (2003) 1208-1214
17. Iversen P.O., Groot P.D., Hjeltnes N., Andersen T.O., Mowinckel M.C., and Sandset P.M. Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia. Br J Haematol 119 (2002) 1011-1016
18. Ditunno Jr. J.F., Young W., Donovan W.H., and Creasey G. The international standards booklet for neurological and functional classification of spinal cord injury. American spinal injury association. Paraplegia 32 (1994) 70-80
19. Misumi K., Ogawa H., Yasue H., Soejima H., Suefuji H., Nishiyama K., et al. Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina. Jpn Circ J 62 (1998) 419-424
20. Zeitzer J.M., Ayas N.T., Shea S.A., Brown R., and Czeisler C.A. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 85 (2000) 2189-2196
21. Claustrat B., Brun J., and Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9 (2005) 11-24
22. Pinotti M., Bertolucci C., Portaluppi F., Colognesi I., Frigato E., Foa A., et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 25 (2005) 646-649
23. Kanabrocki E.L., George M., Hermida R.C., Messmore H.L., Ryan M.D., Ayala D.E., et al. Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin. Clin Appl Thromb Hemost 7 (2001) 339-345
24. Bendz B., Andersen T.O., and Sandset P.M. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. Thromb Res 97 (2000) 463-472
25. Dahm A.E.A., Andersen T.O., Rosendaal F., and Sandset P.M. A novel anticoagulant activity assay of tissue factor pathway inhibitor 1 (TFPI). J Thromb Haemost 3 (2005) 651-658
26. Hansen J.B., Grimsgaard S., Huseby N., Sandset P.M., and Bonaa K.H. Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men. Thromb Res 102 (2001) 3-13
27. Kokawa T., Abumiya T., Kimura T., Harada-Shiba M., Koh H., Tsushima M., et al. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 15 (1995) 504-510
28. Peverill R.E., Teede H.J., Smolich J.J., Malan E., Kotsopoulos D., Tipping P.G., et al. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci 101 (2001) 93-99
29. Hjeltnes N., De Groot P., Birkeland K.I., Falch J.A., and Iversen P.O. Tetraplegic subjects have hyperleptinaemia with marked circadian variation. Clin Endocrinol 62 (2005) 223-227
30. Muller J.E., Stone P.H., Turi Z.G., Rutherford J.D., Czeisler C.A., Parker C., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 (1985) 1315-1322
31. Marler J.R., Price T.R., Clark G.L., Muller J.E., Robertson T., Mohr J.P., et al. Morning increase in onset of ischemic stroke. Stroke 20 (1989) 473-476
32. Manfredini R., Gallerani M., Portaluppi F., Salmi R., Zamboni P., and Fersini C. Circadian variation in the onset of acute critical limb ischemia. Thromb Res 92 (1998) 163-169
33. Andreotti F., and Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 8 (1991) 336-351
34. Iversen PO, Dahm A, Sandset PM. Circadian variations within the hemostatic and fibrinolytic systems, with emphasis on venous thromboembolism. In: Columbus F, editor. Trend in chronobiology research. New York: Nova Science Publishers Inc; in press.
35. Morange P.E., Simon C., Alessi M.C., Luc G., Arveiler D., Ferrieres J., et al. Endothelial cell markers and the risk of coronary heart disease: the prospective epidemiological study of myocardial infarction (PRIME) study. Circulation 109 (2004) 1343-1348